[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.65.227. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 17, 1997

Bioequivalence of Levothyroxine Preparations: Issues of Science, Publication, and Advertising

Author Affiliations

Epidemiology Resources Inc Newton Lower Falls, Mass

JAMA. 1997;278(11):897. doi:10.1001/jama.1997.03550110035023
Abstract

To the Editor.  —Some readers may mistakenly infer from the unfortunate experience of Dr Dong and colleagues1 that any collaboration with industry requires a researcher to sell his or her soul, or at least his or her independence. To the contrary, any health scientist who conducts industry-sponsored work can and should demand guarantees to publish at the outset of any project. True, the culture of business is based on proprietary research rather than open publication of findings as the primary goal. But I know that this gap can be bridged because we have done it for the past 16 years from the cloutless position of a small private company. We have conducted contract research for many drug companies, and insist on full control over publication. With this policy we occasionally lose a potential client who cannot abide the risk of uncontrolled publication, but this loss is more than balanced by those who

×